Earlier this year the Innovative Genomics Institute and the life sciences tools conglomerate Danaher launched a collaborative center to develop genome-editing therapies for rare and other diseases. The Danaher-IGI Beacon for CRISPR Cures seeks to address hundreds of diseases with a unified research, development, and regulatory approach. Their goal is to create a new model for the development of genomic medicines. We spoke to Fyodor Urnov, IGI’s director of technology and translation and director of the new Beacon center, about the evolution of gene editing technology, the challenges of a platform approach, and how the organization plans to share what it learns.
Keeping Clinical Trials Running Smoothly
A Vision for Patient-Centric Gene Therapy Development
Using Genetic Testing to Address Disparities in Care for Kidney Disease
Why Reforms to the Accelerated Approval Pathway Threaten Rare Disease Drug Development
A Longstanding Academic-Nonprofit Collaboration Gives Rise to an ALS Drug Company
Targeting Regulatory RNA to Upregulate Gene Expression to Treat Rare Diseases
Developing a New Approach to Treat Rare, Autoimmune Conditions
Bridging the Gap Between Basic and Commercial Research for Rare Disease
Stoking Functional Copies of Genes to Compensate for Mutated Ones
Targeting ALS with Synergistic Combinations of Therapies
How a Polish Rare Disease Organizations Is Helping Its Ukrainian Neighbors
Powering a New Era of Genetic Medicine
Searching for a Diagnosis
A Novel Way to Deliver Rare Disease Therapies
Bringing Diversity, Equity, and Inclusion to the Books We Read
From Mila to Millions: Scaling N of 1 Therapies
Genetically Modifying Patients’ Skin Cells to Treat Rare Diseases
Targeting Rare, Immunologic Disorders
Harnessing a Natural Mechanism to Silence Disease
Advancing Precision Medicine with Patient Data
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
NABOR® TALKS
U.S Property Podcast
Aligned Money Show
The Ramsey Show
Planet Money